Holen Sie sich die Stockscreener-App
25.35
3.58%
-0.94
Handel nachbörslich:
25.38
0.03
+0.12%
Schlusskurs vom Vortag:
$26.29
Offen:
$25.63
24-Stunden-Volumen:
2.40M
Relative Volume:
0.65
Marktkapitalisierung:
$18.83B
Einnahmen:
$956.00K
Nettoeinkommen (Verlust:
$-221.32M
KGV:
-79.22
EPS:
-0.32
Netto-Cashflow:
$-142.25M
1W Leistung:
-1.30%
1M Leistung:
-3.24%
6M Leistung:
+17.36%
1J Leistung:
+106.94%
1-Tages-Spanne:
$25.04
$25.83
1-Wochen-Bereich:
$25.04
$27.84
52-Wochen-Spanne:
$11.76
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
25.35 | 19.83B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Summit stock gets Neutral view at Piper Sandler (SMMT:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Summit Therapeutics at Neutral With $21 Price Target - MarketScreener
Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism - Yahoo Finance
Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call - MSN
Top 3 Growth Stocks to Buy in August: Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals - AInvest
3 Fantastic Growth Stocks to Buy in August - The Globe and Mail
Does Summit Therapeutics Inc. show high probability of rebound2025 Top Gainers & Community Verified Swing Trade Signals - Newser
What is the dividend yield of Summit Therapeutics Inc.2025 Earnings Surprises & Reliable Breakout Stock Forecasts - thegnnews.com
Is it too late to sell Summit Therapeutics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
Cantor Fitzgerald Has Weak Outlook for SMMT FY2025 Earnings - Defense World
Summit Therapeutics (NASDAQ:SMMT) Earns “Buy” Rating from HC Wainwright - Defense World
Summit Therapeutics Inc.’s Beta Climbs After Market VolatilityMarket Sentiment Report & Consistent Profit Trade Alerts - metal.it
Summit Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - Newser
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal - MSN
What makes Summit Therapeutics Inc. stock price move sharplySwing Trade & Smart Investment Allocation Insights - thegnnews.com
How to build a dashboard for Summit Therapeutics Inc. stock2025 Market WrapUp & Expert-Curated Trade Recommendations - Newser
11 Best Short Squeeze Stocks to Buy Now - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Downgraded to Sell Rating by Wall Street Zen - Defense World
Pattern recognition hints at Summit Therapeutics Inc. upsidePortfolio Gains Report & Proven Capital Preservation Methods - Newser
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday - MSN
Strategies to average down on Summit Therapeutics Inc.July 2025 Fed Impact & Real-Time Market Trend Scan - Newser
Summit Therapeutics Faces Questions Over Its Cash Burn And Future - Finimize
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 - Stock Titan
Custom Dashboard Highlights Summit Therapeutics Inc. Price MomentumJuly 2025 Technicals & Reliable Intraday Trade Plans - beatles.ru
Summit Therapeutics Pullback Seen as 'Overreaction' Amid Liquidity Options, Truist Says - 富途牛牛
Why Summit Therapeutics Shares Are Poised for Growth - TipRanks
A Quick Look at Today's Ratings for Summit Therapeutics(SMMT.US), With a Forecast Between $33 to $35 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Glaukos (GKOS) - The Globe and Mail
Evercore ISI Issues Positive Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock Price - Defense World
Summit Therapeutics shares rise 2.16% premarket after earnings results reported. - AInvest
10 Stocks That Vanished in Value - Insider Monkey
Summit Therapeutics’ Promising Advancements in Cancer Treatment Drive Buy Rating - TipRanks
SMMT Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Positive Outlook for Summit Therapeutics: Buy Rating Supported by Financial Stability and Strategic Developments - TipRanks
Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’ - TipRanks
Summit Therapeutics Plummets 11.9% Amid Legal Storm: What’s Brewing in Biotech? - AInvest
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus - Nasdaq
Summit Therapeutics price target raised to $33 from $30 at Clear Street - TipRanks
Evercore ISI Group Raises Summit Therapeutics PT to $34, Maintains Outperform Rating - AInvest
Summit Therapeutics stock price target raised to $34 by Evercore ISI - Investing.com Canada
Summit Therapeutics shares fall 3.72% premarket after reporting Q2 financial results and operational updates. - AInvest
Summit Therapeutics Inc. Securities Fraud LawsuitClass Action Opportunity - AInvest
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm - Barchart.com
Summit Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Summit Therapeutics Q2 Loss Widens to $0.12 per Share - AInvest
Summit Therapeutics Q2 Adjusted Loss Widens - MarketScreener
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Placera.se
Summit Therapeutics Amends Stock Distribution Agreement - TipRanks
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.12 per Share, vs. FactSet Est of $-0.10 - MarketScreener
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Summit Therapeutics Inc-Aktie (SMMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.64%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):